Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody Targeting Two Immune Checkpoints

Onward Therapeutics Denmark Finland Germany Netherlands Sweden United Kingdom Switzerland France

View original content:https://www.prnewswire.co.uk/news-releases/onward-therapeutics-announces-enrollment-of-phase-1-clinical-trial-of-a-novel-bispecific-antibody-ot-a201-targeting-two-immune-checkpoints-302042066.html